Literature DB >> 12493803

Antifungal activity of the echinocandin anidulafungin (VER002, LY-303366) against yeast pathogens: a comparative study with M27-A microdilution method.

María Pilar Arévalo1, Alfonso-Javier Carrillo-Muñoz, Javier Salgado, Delia Cardenes, Sonia Brió, Guillermo Quindós, Ana Espinel-Ingroff.   

Abstract

This study further evaluated the in vitro activity of anidulafungin (VER002, Versicor Inc.) (LY303366) against 460 clinical yeast isolates. MICs of anidulafungin, fluconazole and itraconazole were determined by following the NCCLS M27-A guidelines. Minimum fungicidal concentrations (MFCs) of anidulafungin were determined for 230 isolates of Candida spp. The activity of anidulafungin in vitro was significantly superior (P < 0.05) to those of itraconazole and fluconazole against Candida albicans, Candida tropicalis, Candida glabrata and Candida krusei, but anidulafungin was less active for Candida famata and Candida parapsilosis. The differences were not significant for the other species evaluated.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12493803     DOI： 10.1093/jac/dkg018

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN： 0305-7453            Impact factor:   5.790


  10 in total

Review 1.  Determination of fungicidal activities against yeasts and molds: lessons learned from bactericidal testing and the need for standardization.

Authors:  M A Pfaller; D J Sheehan; J H Rex
Journal:  Clin Microbiol Rev       Date:  2004-04       Impact factor: 26.132

2.  In vitro activity of anidulafungin and other agents against esophageal candidiasis-associated isolates from a phase 3 clinical trial.

Authors:  M A Pfaller; R Hollis; B P Goldstein; S Messer; D Diekema; T Henkel
Journal:  J Clin Microbiol       Date:  2010-05-26       Impact factor: 5.948

3.  In vitro pharmacodynamics of anidulafungin and caspofungin against Candida glabrata isolates, including strains with decreased caspofungin susceptibility.

Authors:  Jason Cota; Michael Carden; John R Graybill; Laura K Najvar; David S Burgess; Nathan P Wiederhold
Journal:  Antimicrob Agents Chemother       Date:  2006-08-28       Impact factor: 5.191

4.  Effectiveness of anidulafungin in eradicating Candida species in invasive candidiasis.

Authors:  M A Pfaller; D J Diekema; L Boyken; S A Messer; S Tendolkar; R J Hollis; B P Goldstein
Journal:  Antimicrob Agents Chemother       Date:  2005-11       Impact factor: 5.191

5.  In vitro activities of anidulafungin against more than 2,500 clinical isolates of Candida spp., including 315 isolates resistant to fluconazole.

Authors:  M A Pfaller; L Boyken; R J Hollis; S A Messer; S Tendolkar; D J Diekema
Journal:  J Clin Microbiol       Date:  2005-11       Impact factor: 5.948

6.  In vivo efficacy of anidulafungin and caspofungin against Candida glabrata and association with in vitro potency in the presence of sera.

Authors:  Nathan P Wiederhold; Laura K Najvar; Rosie Bocanegra; Destiny Molina; Marcos Olivo; John R Graybill
Journal:  Antimicrob Agents Chemother       Date:  2007-02-16       Impact factor: 5.191

7.  In vitro activity of seven systemically active antifungal agents against a large global collection of rare Candida species as determined by CLSI broth microdilution methods.

Authors:  D J Diekema; S A Messer; L B Boyken; R J Hollis; J Kroeger; S Tendolkar; M A Pfaller
Journal:  J Clin Microbiol       Date:  2009-08-26       Impact factor: 5.948

8.  Anidulafungin.

Authors:  David Murdoch; Greg L Plosker
Journal:  Drugs       Date:  2004       Impact factor: 9.546

9.  Candida famata mediastinitis. A rare complication of open heart surgery. Case report and brief review.

Authors:  Alfredo Alonso Sanchez Betancourt; Pablo Sibaja Alvarez; Rolando Arguedas Camacho; Edward Guevara Espinoza
Journal:  IDCases       Date:  2016-07-04

10.  Caspofungin for the treatment of immunocompromised and severely ill children and neonates with invasive fungal infections.

Authors:  Nathan P Wiederhold; Lydia A Herrera
Journal:  Clin Med Insights Pediatr       Date:  2012-06-07
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.